MeiraGTx Holdings (MeiraGTx Holdings) EBITDA Margin % : -1,996.70% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is MeiraGTx Holdings EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. MeiraGTx Holdings's EBITDA for the three months ended in Mar. 2024 was $-13.92 Mil. MeiraGTx Holdings's Revenue for the three months ended in Mar. 2024 was $0.70 Mil. Therefore, MeiraGTx Holdings's EBITDA margin for the quarter that ended in Mar. 2024 was -1,996.70%.

MeiraGTx Holdings EBITDA Margin % Historical Data

The historical data trend for MeiraGTx Holdings's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MeiraGTx Holdings EBITDA Margin % Chart

MeiraGTx Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBITDA Margin %

Get a 7-Day Free Trial

-394.67

-344.93

-189.38

-729.06

-407.06

MeiraGTx Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBITDA Margin %	Get a 7-Day Free Trial															-726.21	-649.12	-733.63	1,351.47	-1,996.70

Competitive Comparison of MeiraGTx Holdings's EBITDA Margin %

For the Biotechnology subindustry, MeiraGTx Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MeiraGTx Holdings's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MeiraGTx Holdings's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where MeiraGTx Holdings's EBITDA Margin % falls into.

MeiraGTx Holdings EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

MeiraGTx Holdings's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-57.058	/	14.017
	=	-407.06 %

MeiraGTx Holdings's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-13.917	/	0.697
	=	-1,996.70 %

MeiraGTx Holdings (NAS:MGTX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

MeiraGTx Holdings EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of MeiraGTx Holdings's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

MeiraGTx Holdings (MeiraGTx Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MeiraGTx Holdings PLC (NAS:MGTX) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

328:Germany

Address

450 East 29th Street, 14th Floor, New York, NY, USA, 10016

Website

https://www.meiragtx.com

MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.

Executives

Perceptive Life Sciences Master Fund Ltd	director, 10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Johnson & Johnson Innovation - Jjdc, Inc.	10 percent owner	410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Johnson & Johnson	10 percent owner	ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ 08933
Robert K Zeldin	officer: Chief Medical Officer	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Robert J Wollin	officer: General Counsel and Secretary	450 EAST 29TH STREET, 14TH FLOOR, NEW YORK NY 10016
Debra Yu	director	C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Alexandria Forbes	director, officer: President & CEO	C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016
Richard Giroux	officer: Chief Operating Officer	C/O MEIRAGTX - US, 430 EAST 29TH STREET, 10TH FLOOR, NEW YORK NY 10016
Stuart Naylor	director, officer: Chief Dev. Officer	C/O MEIRAGTX - US, 430 EAST 29TH STREET, 10TH FLOOR, NEW YORK NY 10016
Joel S Marcus	director	C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Thomas E Shenk	director	C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016
Nicole Seligman	director	C/O VIACOM INC., 1515 BROADWAY, NEW YORK NY 10036
Perceptive Advisors Llc	director, 10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Ellen Hukkelhoven	director	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003